Progress and application of epitranscriptomic m6A modification in gastric cancer

RNA Biol. 2022 Jan;19(1):885-896. doi: 10.1080/15476286.2022.2096793.

Abstract

The relationship between epitranscriptomics and malignant tumours has become a popular research topic in recent years. N6-methyladenosine (m6A), the most common post-transcriptional modification in mammals, is involved in various physiological processes in different cancer types, including gastric cancer (GC). The incidence and mortality of GC have been increasing annually, especially in developing countries. Insights into the epitranscriptomic mechanisms of gastric carcinogenesis could provide potential strategies for the prevention, diagnosis, and treatment of GC. In this review, we describe the mechanisms of RNA m6A modification; the functions of m6A regulators in GC; the functional crosstalk among m6A, messenger RNA, and noncoding RNA; and the promising application of m6A in the diagnosis and treatment of GC.

Keywords: Epitranscriptome; gastric cancer; m6A; messenger RNA; noncoding RNA.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine / genetics
  • Animals
  • Carcinogenesis
  • Mammals
  • RNA, Messenger
  • Stomach Neoplasms* / genetics

Substances

  • RNA, Messenger
  • Adenosine

Grants and funding

This review is supported by the National Natural Science Foundation of China (No.82072662, No. 81772526), Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant Support (2016142), Medical Engineering Intersection Project of Shanghai Jiao Tong University (YG2017MS28), Shanghai three-year action plan to promote clinical skills and clinical innovation in municipal hospitals (SHDC2020CR4022), and the 2021 Shanghai ‘Rising Stars of Medical Talent’ Youth Development Program: Outstanding Youth Medical Talents.the 2021 Shanghai “Rising Stars of Medical Talent” Youth Development Program: Outstanding Youth Medical Talents.